COVID-19 vaccines: Difference between revisions
Jose Loyola (talk | contribs) |
Jose Loyola (talk | contribs) |
||
| Line 12: | Line 12: | ||
===Pfizer/BioNtech Comirnaty BNT162b2=== | ===Pfizer/BioNtech Comirnaty BNT162b2=== | ||
It was approved for emergency use in December 11, 2020. It has been shown to have an efficacy of | It was approved for emergency use in December 11, 2020. It has been shown to have an efficacy of 95% at preventing COVID-19 in persons 16 years of age or older.<ref name="pmid33301246">{{cite journal| author=Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S | display-authors=etal| title=Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. | journal=N Engl J Med | year= 2020 | volume= 383 | issue= 27 | pages= 2603-2615 | pmid=33301246 | doi=10.1056/NEJMoa2034577 | pmc=7745181 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33301246 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=&cmd=prlinks&id=33524290 Review in: Ann Intern Med. 2021 Feb;174(2):JC15] </ref> Its protection against severe COVID-19 was shown to be of approximately 97%. New analysis showed that after six months its efficacy fell to 84%, which is not known if this is due to the vaccine and immune system themselves of if the emergence of variants are affecting the efficacy of the vaccine. | ||
As for side effects, the vaccine has been reported to cause mostly mild symptoms such as myalgia, headaches and soreness in the location where it was applied. Allergic reactions have also been reported in a few patients | As for side effects, the vaccine has been reported to cause mostly mild symptoms such as myalgia, headaches and soreness in the location where it was applied. Allergic reactions have also been reported in a few patients, and they all recovered quickly after an epinephrine shot.<ref name="pmid33426427">{{cite journal| author=Kleine-Tebbe J, Klimek L, Hamelmann E, Pfaar O, Taube C, Wagenmann M | display-authors=etal| title=Severe allergic reactions to the COVID-19 vaccine - statement and practical consequences. | journal=Allergol Select | year= 2021 | volume= 5 | issue= | pages= 26-28 | pmid=33426427 | doi=10.5414/ALX02215E | pmc=7787363 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33426427 }} </ref> It has also been reported to be associated with myocarditis, especially in young men, but the cases reported so far were mild and recovered. | ||
*Dose regimen: | *Dose regimen: | ||
**Application of 2 doses, spaced by 21 days between shots. | **Application of 2 doses, spaced by 21 days between shots. | ||
Revision as of 23:53, 14 August 2021
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 vaccines On the Web |
|
American Roentgen Ray Society Images of COVID-19 vaccines |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
On December 11, 2020, the F.D.A. authorized Pfizer's vaccine for emergency use for the prevention of COVID-19. Since then, many other vaccines have been developed, such as the ones from Moderna, AstraZeneca, Janssen, Sinovac, Sinopharm and Gamaleya. Efficacy, side effect and safety profiles vary dramatically between them, as they are produced using different mechanisms.
Vaccines
Pfizer/BioNtech Comirnaty BNT162b2
It was approved for emergency use in December 11, 2020. It has been shown to have an efficacy of 95% at preventing COVID-19 in persons 16 years of age or older.[1] Its protection against severe COVID-19 was shown to be of approximately 97%. New analysis showed that after six months its efficacy fell to 84%, which is not known if this is due to the vaccine and immune system themselves of if the emergence of variants are affecting the efficacy of the vaccine. As for side effects, the vaccine has been reported to cause mostly mild symptoms such as myalgia, headaches and soreness in the location where it was applied. Allergic reactions have also been reported in a few patients, and they all recovered quickly after an epinephrine shot.[2] It has also been reported to be associated with myocarditis, especially in young men, but the cases reported so far were mild and recovered.
- Dose regimen:
- Application of 2 doses, spaced by 21 days between shots.
- A third shot was recently recommended by the F.D.A. for immunocompromised patients.
Moderna
The clinical trials produced by Moderna showed that its vaccine has an efficacy of 90% against symptomatic COVID-19 and 95% efficacy against severe disease after six months. As its
Janssen
AstraZeneca
Covaxin
CoronaVac
Sputnik
- ↑ Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S; et al. (2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". N Engl J Med. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181 Check
|pmc=value (help). PMID 33301246 Check|pmid=value (help). Review in: Ann Intern Med. 2021 Feb;174(2):JC15 - ↑ Kleine-Tebbe J, Klimek L, Hamelmann E, Pfaar O, Taube C, Wagenmann M; et al. (2021). "Severe allergic reactions to the COVID-19 vaccine - statement and practical consequences". Allergol Select. 5: 26–28. doi:10.5414/ALX02215E. PMC 7787363 Check
|pmc=value (help). PMID 33426427 Check|pmid=value (help).